Montelukast cuts use, cost of asthma/allergy medications

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1511, 2005-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Implications for the Use of Inhaled Anti-Inflammatory Medications in the Treatment of Asthma

By Ozminkowski R.J.

PharmacoEconomics, Vol. 18, Iss. 3, 2000-09 ,pp. : 253-264

Adis International

Access to resources Recommend Favorite

Montelukast reduces resource use in asthma/SAR

Inpharma, Vol. 1, Iss. 1602, 2007-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Montelukast reduces resource use in asthma/SAR

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 535, 2007-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Comparison of Salmeterol/Fluticasone Propionate versus Montelukast in the Treatment of Adults with Persistent Asthma

By Sheth K.

PharmacoEconomics, Vol. 20, Iss. 13, 2002-01 ,pp. : 909-918

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Fluticasone Propionate Plus Salmeterol Versus Fluticasone Propionate Plus Montelukast in the Treatment of Persistent Asthma

By Richard D. OConnor

PharmacoEconomics, Vol. 22, Iss. 12, 2004-01 ,pp. : 815-825

Adis International

Access to resources Recommend Favorite